Hidenori Mizugaki

ORCID

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 10

Top Venues

Cancer science

Cancer medicine

Clinical pharmacology and therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Kosuke Tsuji, Hidenori Mizugaki, Keiki Yokoo, Maki Kobayashi, Yosuke Kawashima, Nozomu Kimura, Hiroshi Yokouchi, Hajime Kikuchi, Toshiyuki Sumi, Yasutaka Kawai, Kenta Kobashi, Ryo Morita, Kenichiro Ito, Yasuo Kitamura, Hiroyuki Minemura, Keiichi Nakamura, Mari Aso, Osamu Honjo, Hisashi Tanaka, Taichi Takashina, Kyoji Tsurumi, Jun Sugisaka, Yoko Tsukita, Satoshi Konno, Satoshi Oizumi
Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR mutation: A real-world study (HOT2101). Cancer science 115 (4) (2024)
Kosuke Tsuji, Hidenori Mizugaki, Keiki Yokoo, Maki Kobayashi, Yosuke Kawashima, Nozomu Kimura, Hiroshi Yokouchi, Hajime Kikuchi, Toshiyuki Sumi, Yasutaka Kawai, Kenta Kobashi, Ryo Morita, Kenichiro Ito, Yasuo Kitamura, Hiroyuki Minemura, Keiichi Nakamura, Mari Aso, Osamu Honjo, Hisashi Tanaka, Taichi Takashina, Kyoji Tsurumi, Jun Sugisaka, Yoko Tsukita, Satoshi Konno, Satoshi Oizumi
Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR mutation: A real-world study (HOT2101). Cancer science 115 (4) (2024)
Kosuke Tsuji, Hidenori Mizugaki, Keiki Yokoo, Maki Kobayashi, Yosuke Kawashima, Nozomu Kimura, Hiroshi Yokouchi, Hajime Kikuchi, Toshiyuki Sumi, Yasutaka Kawai, Kenta Kobashi, Ryo Morita, Kenichiro Ito, Yasuo Kitamura, Hiroyuki Minemura, Keiichi Nakamura, Mari Aso, Osamu Honjo, Hisashi Tanaka, Taichi Takashina, Kyoji Tsurumi, Jun Sugisaka, Yoko Tsukita, Satoshi Konno, Satoshi Oizumi
Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR mutation: A real-world study (HOT2101). Cancer science (2024)
Yasuyuki Ikezawa, Ryo Morita, Hidenori Mizugaki, Kazunari Tateishi, Keiki Yokoo, Toshiyuki Sumi, Hajime Kikuchi, Yasuo Kitamura, Atsushi Nakamura, Maki Kobayashi, Mari Aso, Nozomu Kimura, Fumiaki Yoshiike, Furuta Megumi, Hisashi Tanaka, Motoki Sekikawa, Tsutomu Hachiya, Keiichi Nakamura, Fumihiro Hommura, Noriaki Sukoh, Kenichiro Ito, Takashi Kikuchi, Toshihiko Agatsuma, Hiroshi Yokouchi
Real-world first-line treatment with pembrolizumab for non-small cell lung carcinoma with high PD-L1 expression: Updated analysis. Cancer medicine 13 (14) (2024)
Yasuyuki Ikezawa, Ryo Morita, Hidenori Mizugaki, Kazunari Tateishi, Keiki Yokoo, Toshiyuki Sumi, Hajime Kikuchi, Yasuo Kitamura, Atsushi Nakamura, Maki Kobayashi, Mari Aso, Nozomu Kimura, Fumiaki Yoshiike, Furuta Megumi, Hisashi Tanaka, Motoki Sekikawa, Tsutomu Hachiya, Keiichi Nakamura, Fumihiro Hommura, Noriaki Sukoh, Kenichiro Ito, Takashi Kikuchi, Toshihiko Agatsuma, Hiroshi Yokouchi
Real-world first-line treatment with pembrolizumab for non-small cell lung carcinoma with high PD-L1 expression: Updated analysis. Cancer medicine 13 (14) (2024)
Yasuyuki Ikezawa, Ryo Morita, Hidenori Mizugaki, Kazunari Tateishi, Keiki Yokoo, Toshiyuki Sumi, Hajime Kikuchi, Yasuo Kitamura, Atsushi Nakamura, Maki Kobayashi, Mari Aso, Nozomu Kimura, Fumiaki Yoshiike, Furuta Megumi, Hisashi Tanaka, Motoki Sekikawa, Tsutomu Hachiya, Keiichi Nakamura, Fumihiro Hommura, Noriaki Sukoh, Kenichiro Ito, Takashi Kikuchi, Toshihiko Agatsuma, Hiroshi Yokouchi
Real-world first-line treatment with pembrolizumab for non-small cell lung carcinoma with high PD-L1 expression: Updated analysis. Cancer medicine 13 (14) (2024)
Shigehiro Yagishita, Yuta Yamanaka, Takayasu Kurata, Kageaki Watanabe, Yukio Hosomi, Hidehito Horinouchi, Yuichiro Ohe, Yoshiro Nakahara, Katsuhiko Naoki, Tetsuhiko Asao, Kazuhisa Takahashi, Sho Saeki, Takuro Sakagami, Kazuhisa Nakashima, Yukari Tsubata, Yu Fujita, Kazuyoshi Kuwano, Megumi Furuta, Jun Sakakibara Konishi, Mayu Ohuchi, Yuichi Ando, Hidenori Mizugaki, Akinobu Hamada
Multicenter Pharmacokinetic and Pharmacodynamic Study of Pembrolizumab for Non-small-Cell Lung Cancer in Patients Aged 75 Years and Older. Clinical pharmacology and therapeutics (2024)
Kosuke Tsuji, Hidenori Mizugaki, Keiki Yokoo, Maki Kobayashi, Yosuke Kawashima, Nozomu Kimura, Hiroshi Yokouchi, Hajime Kikuchi, Toshiyuki Sumi, Yasutaka Kawai, Kenta Kobashi, Ryo Morita, Kenichiro Ito, Yasuo Kitamura, Hiroyuki Minemura, Keiichi Nakamura, Mari Aso, Osamu Honjo, Hisashi Tanaka, Taichi Takashina, Kyoji Tsurumi, Jun Sugisaka, Yoko Tsukita, Satoshi Konno, Satoshi Oizumi
Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR mutation: A real-world study (HOT2101). Cancer science 115 (4) (2024)
Kosuke Tsuji, Hidenori Mizugaki, Keiki Yokoo, Maki Kobayashi, Yosuke Kawashima, Nozomu Kimura, Hiroshi Yokouchi, Hajime Kikuchi, Toshiyuki Sumi, Yasutaka Kawai, Kenta Kobashi, Ryo Morita, Kenichiro Ito, Yasuo Kitamura, Hiroyuki Minemura, Keiichi Nakamura, Mari Aso, Osamu Honjo, Hisashi Tanaka, Taichi Takashina, Kyoji Tsurumi, Jun Sugisaka, Yoko Tsukita, Satoshi Konno, Satoshi Oizumi
Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR mutation: A real-world study (HOT2101). Cancer science 115 (4) (2024)
Yasuyuki Ikezawa, Hidenori Mizugaki, Ryo Morita, Kazunari Tateishi, Keiki Yokoo, Toshiyuki Sumi, Hajime Kikuchi, Yasuo Kitamura, Atsushi Nakamura, Maki Kobayashi, Mari Aso, Nozomu Kimura, Fumiaki Yoshiike, Megumi Furuta, Hisashi Tanaka, Motoki Sekikawa, Tsutomu Hachiya, Keiichi Nakamura, Mototsugu Shimokawa, Satoshi Oizumi
Current status of first-line treatment with pembrolizumab for non-small-cell lung cancer with high PD-L1 expression. Cancer science 113 (6) (2022)

Hidenori Mizugaki.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Hidenori Mizugaki